Justin Walsh
Stock Analyst at Jones Trading
(1.77)
# 3,065
Out of 4,711 analysts
31
Total ratings
32.26%
Success rate
-8.06%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $3.89 | +362.72% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $18.07 | +132.43% | 1 | Oct 18, 2024 | |
| THTX Theratechnologies | Downgrades: Hold | n/a | $1.79 | - | 2 | Oct 11, 2024 | |
| BLRX BioLineRx | Initiates: Buy | $2 | $0.20 | +885.22% | 1 | Sep 4, 2024 | |
| LNTH Lantheus Holdings | Maintains: Buy | $105 → $146 | $89.29 | +63.52% | 7 | Jul 25, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $23 | $8.28 | +177.78% | 1 | Jul 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $15 → $22 | $2.85 | +671.93% | 2 | May 16, 2024 | |
| TLSI TriSalus Life Sciences | Initiates: Buy | $16 | $4.05 | +295.06% | 1 | May 10, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $20 | $3.69 | +442.01% | 1 | Apr 17, 2024 | |
| CTSO Cytosorbents | Reinstates: Buy | $4 | $0.92 | +337.16% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.90 | +589.66% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $0.87 | +1,975.41% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $6.68 | +6,486.83% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $1.09 | +6,780.73% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $34.22 | -41.55% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $3.08 | +6,393.51% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.38 | +624.64% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $800 | $5.96 | +13,322.82% | 1 | Sep 2, 2021 |
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $3.89
Upside: +362.72%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $18.07
Upside: +132.43%
Theratechnologies
Oct 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.79
Upside: -
BioLineRx
Sep 4, 2024
Initiates: Buy
Price Target: $2
Current: $0.20
Upside: +885.22%
Lantheus Holdings
Jul 25, 2024
Maintains: Buy
Price Target: $105 → $146
Current: $89.29
Upside: +63.52%
Y-mAbs Therapeutics
Jul 11, 2024
Initiates: Buy
Price Target: $23
Current: $8.28
Upside: +177.78%
Perspective Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $2.85
Upside: +671.93%
TriSalus Life Sciences
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $4.05
Upside: +295.06%
Achieve Life Sciences
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $3.69
Upside: +442.01%
Cytosorbents
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.92
Upside: +337.16%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $2.90
Upside: +589.66%
May 16, 2023
Initiates: Buy
Price Target: $18
Current: $0.87
Upside: +1,975.41%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $6.68
Upside: +6,486.83%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $1.09
Upside: +6,780.73%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $34.22
Upside: -41.55%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $3.08
Upside: +6,393.51%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $1.38
Upside: +624.64%
Sep 2, 2021
Initiates: Buy
Price Target: $800
Current: $5.96
Upside: +13,322.82%